<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM12672</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-12672</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Взаимосвязь рака предстательной железы и сахарного диабета второго типа</article-title><trans-title-group xml:lang="en"><trans-title>Relationship between prostate cancer and type 2 diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1497-8646</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пешков</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Peshkov</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пешков Максим Николаевич, к.м.н.</p><p>SPIN: 1691-1478</p><p>125371, Москва, Волоколамское ш., д. 91</p></bio><bio xml:lang="en"><p>Maxim N. Peshkov, MD, PhD</p><p>SPIN: 1691-1478</p><p>91 Volokolamskoye Highway street, 125371 Moscow</p><p> </p></bio><email xlink:type="simple">Drpeshkov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3336-4025</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пешкова</surname><given-names>Г. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Peshkova</surname><given-names>G. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пешкова Галина Петровна, к.м.н.</p><p>SPIN: 6849-5407</p><p>Рязань</p></bio><bio xml:lang="en"><p>Galina P. Peshkova, MD, PhD</p><p>SPIN: 6849-5407</p><p>Ryazan</p></bio><email xlink:type="simple">gppeshkova@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5739-3170</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Решетов</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Reshetov</surname><given-names>Igor V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Решетов Игорь Владимирович, д.м.н.</p><p>SPIN: 3845-6604;</p><p>Москва</p></bio><bio xml:lang="en"><p>Igor V. Reshetov, MD, PhD</p><p>SPIN: 3845-6604</p><p>Moscow</p></bio><email xlink:type="simple">reshetoviv@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Академия последипломного образования ФГБУ ФНКЦ ФМБА России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academy of postgraduate education under FSCC of FMBA of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Рязанский государственный медицинский университет имени академика И.П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ryazan State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical Univesity (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>17</day><month>12</month><year>2021</year></pub-date><volume>24</volume><issue>6</issue><fpage>583</fpage><lpage>591</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Пешков М.Н., Пешкова Г.П., Решетов И.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Пешков М.Н., Пешкова Г.П., Решетов И.В.</copyright-holder><copyright-holder xml:lang="en">Peshkov M.N., Peshkova G.P., Reshetov I.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/12672">https://www.dia-endojournals.ru/jour/article/view/12672</self-uri><abstract><p>Сахарный диабет 2 типа (СД2) и рак предстательной железы являются широко распространенными заболеваниями во всем мире. СД2 выражается нарушением контроля гликемии, гиперинсулинемией, инсулинорезистентностью (ИР). Накопление глюкозы и липидов приводит к уменьшению плотности инсулиновых рецепторов и развитию ИР в жировой ткани. Это способствует развитию гиперинсулинемии, что подавляет распад жиров и приводит к прогрессированию ожирения. Развивается порочный круг: ИР → гиперинсулинемия → ожирение → ИР. В исследованиях последнего времени показана сильная прямая корреляционная связь между уровнем инсулина натощак и смертностью от рака у мужчин. Это может быть особенно актуально у пациентов старше 65 лет, которые в  первую очередь более склонны к развитию рака простаты, чем молодые пациенты. Стоит отметить, что именно инсулин, а не глюкоза, связан с риском развития онкологических заболеваний. Инсулин оказывает влияние на прогрессирование клеточного цикла, пролиферацию и метастатическую активность опухоли. Гиперинсулинемия, которая часто возникает в результате андрогенной депривационной терапии (АДТ) — стандартного лечения рака предстательной железы, связана с высокой агрессивностью опухоли и более быстрой неэффективностью проводимой терапии — развитием кастрат-рефрактерного рака предстательной железы. Разумно предположить, что гиперинсулинемия — какими бы обстоятельствами она ни вызывалась, будь то АДТ или неправильное питание и другие факторы образа жизни — может оказывать такое же негативное влияние на передачу сигналов клетками.Метаболический синдром — по существу, хронически повышенный уровень инсулина — тесно связан с рецидивом онкологических заболеваний и худшими исходами после лечения, что побудило исследователей усомниться в общепринятых диетических рекомендациях для больных раком, особенно когда они проходят лечение или выздоравливают после лечения, которое может включать рекомендации употреблять все, что поможет поддерживать или восстанавливать вес тела, независимо от содержания углеводов или его влияния на уровень инсулина. Большое количество пациентов живут с гиперинсулинемией, но нормогликемией. Хроническая гиперинсулинемия является основной движущей силой кардиометаболических заболеваний, даже когда уровень глюкозы в крови в пределах референсных значений. Масштаб данной проблемы не осознан медицинским и научным сообществом.</p></abstract><trans-abstract xml:lang="en"/><kwd-group xml:lang="ru"><kwd>рак предстательной железы</kwd><kwd>метаболический синдром</kwd><kwd>сахарный диабет</kwd><kwd>инсулинорезистентность</kwd><kwd>индекс&#13;
массы тела</kwd><kwd>ожирение</kwd><kwd>дислипидемия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>рrostate cancer</kwd><kwd>metabolic syndrome</kwd><kwd>diabetes mellitus</kwd><kwd>insulin resistance</kwd><kwd>Body Mass Index (BMI)</kwd><kwd>obesity</kwd><kwd>dyslipidemia</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Обзорно-аналитическая работа по подготовке рукописи проведена на личные средства автора.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. doi: https://doi.org/10.3322/caac.21551.</mixed-citation><mixed-citation xml:lang="en">Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. doi: https://doi.org/10.3322/caac.21551.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Состояние онкологической помощи населению России в 2019 году. / Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. — М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2020. 236 с.</mixed-citation><mixed-citation xml:lang="en">State of oncological care in Russia in 2020. Ed by Kaprin АD, Starinskiy VV, Shachzadova AO. Moscow: MNIOI im. P.A. Gertsena — filial FGBU “NMIRTS radiologii” Minzdrava Rossii; 2020. 236 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86:s843–s857. doi: https://doi.org/10.1093/ajcn/86.3.843S</mixed-citation><mixed-citation xml:lang="en">Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86:s843–s857. doi: https://doi.org/10.1093/ajcn/86.3.843S</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Esposito K, Chiodini P, Capuano A, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest. 2013;36:132-139. doi: https://doi.org/10.1007/BF03346748</mixed-citation><mixed-citation xml:lang="en">Esposito K, Chiodini P, Capuano A, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest. 2013;36:132-139. doi: https://doi.org/10.1007/BF03346748</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35:2402–2411. doi: https://doi.org/10.2337/dc12-0336</mixed-citation><mixed-citation xml:lang="en">Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35:2402–2411. doi: https://doi.org/10.2337/dc12-0336</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Keum N, Greenwood DC, Lee DH, et al. Adult Weight Gain and Adiposity-Related Cancers: A Dose-Response Meta-Analysis of Prospective Observational Studies. JNCI J Natl Cancer Inst. 2015;107(2). doi: https://doi.org/10.1093/jnci/djv088</mixed-citation><mixed-citation xml:lang="en">Keum N, Greenwood DC, Lee DH, et al. Adult Weight Gain and Adiposity-Related Cancers: A Dose-Response Meta-Analysis of Prospective Observational Studies. JNCI J Natl Cancer Inst. 2015;107(2). doi: https://doi.org/10.1093/jnci/djv088</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pandeya DR, Mittal A, Sathian B, et al. Role of hyperinsulinemia in increased risk of prostate cancer: a case control study of the Kathmandu Valley. Asian Pac J Cancer Prev. 2014;15:1031-1033. doi: https://doi.org/10.7314/apjcp.2014.15.2.1031</mixed-citation><mixed-citation xml:lang="en">Pandeya DR, Mittal A, Sathian B, et al. Role of hyperinsulinemia in increased risk of prostate cancer: a case control study of the Kathmandu Valley. Asian Pac J Cancer Prev. 2014;15:1031-1033. doi: https://doi.org/10.7314/apjcp.2014.15.2.1031</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">De Nunzio C, Aronson W, Freedland SJ, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570. doi: https://doi.org/10.1016/j.eururo.2011.11.013</mixed-citation><mixed-citation xml:lang="en">De Nunzio C, Aronson W, Freedland SJ, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570. doi: https://doi.org/10.1016/j.eururo.2011.11.013</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015; 67:825-836. doi: https://doi.org/10.1016/j.eururo.2014.07.010</mixed-citation><mixed-citation xml:lang="en">Nguyen PL, Alibhai SMH, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015; 67:825-836. doi: https://doi.org/10.1016/j.eururo.2014.07.010</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645. doi: https://doi.org/10.1161/CIRCULATIONAHA.109.192644</mixed-citation><mixed-citation xml:lang="en">Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645. doi: https://doi.org/10.1161/CIRCULATIONAHA.109.192644</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev. 2001;23:3-13. doi: https://doi.org/10.1093/oxfordjournals.epirev.a000792</mixed-citation><mixed-citation xml:lang="en">Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev. 2001;23:3-13. doi: https://doi.org/10.1093/oxfordjournals.epirev.a000792</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Han JH, Choi NY, Bang SH, et al. Relationship between serum prostate-specific antigen levels and components of metabolic syndrome in healthy men. Urology. 2008;72:749-754. doi: https://doi.org/10.1016/j.urology.2008.01.084</mixed-citation><mixed-citation xml:lang="en">Han JH, Choi NY, Bang SH, et al. Relationship between serum prostate-specific antigen levels and components of metabolic syndrome in healthy men. Urology. 2008;72:749-754. doi: https://doi.org/10.1016/j.urology.2008.01.084</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456. doi: https://doi.org/10.1200/JCO.2006.06.2497</mixed-citation><mixed-citation xml:lang="en">Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456. doi: https://doi.org/10.1200/JCO.2006.06.2497</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом: Клинические рекомендации (Вып. 9) // Сахарный диабет. — 2019. — Т. 22. — №S1. — С.1-144. doi: https://doi.org/10.14341/DM221S1</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Diabetes Mellitus. 2019;22(S1):1-144 (In Russ.). doi: https://doi.org/10.14341/DM221S1</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607. doi: https://doi.org/10.1136/bmj.g7607</mixed-citation><mixed-citation xml:lang="en">Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:g7607. doi: https://doi.org/10.1136/bmj.g7607</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071-1078. doi: https://doi.org/10.1007/s00125-004-1415-6</mixed-citation><mixed-citation xml:lang="en">Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071-1078. doi: https://doi.org/10.1007/s00125-004-1415-6</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2056-2062. doi: https://doi.org/10.1158/1055-9965.EPI-06-0410</mixed-citation><mixed-citation xml:lang="en">Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2056-2062. doi: https://doi.org/10.1158/1055-9965.EPI-06-0410</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bansal D, Bhansali A, Kapil G, et al. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16(2):151-158. doi: https://doi.org/10.1038/pcan.2012.40</mixed-citation><mixed-citation xml:lang="en">Bansal D, Bhansali A, Kapil G, et al. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16(2):151-158. doi: https://doi.org/10.1038/pcan.2012.40</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Jian Gang P, Mo L, Lu Y, et al. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. Endocr Res. 2015;40(1):54-61. doi: https://doi.org/10.3109/07435800.2014.934961</mixed-citation><mixed-citation xml:lang="en">Jian Gang P, Mo L, Lu Y, et al. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. Endocr Res. 2015;40(1):54-61. doi: https://doi.org/10.3109/07435800.2014.934961</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Dankner R, Boffetta P, Balicer RD, et al. Time-dependent Risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016;183(12):1098-1106. doi: https://doi.org/10.1093/aje/kwv290</mixed-citation><mixed-citation xml:lang="en">Dankner R, Boffetta P, Balicer RD, et al. Time-dependent Risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol. 2016;183(12):1098-1106. doi: https://doi.org/10.1093/aje/kwv290</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Tsilidis KK, Allen NE, Appleby PN, et al Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition Int J Cancer. 2015;136(2):372-381. doi: https://doi.org/10.1002/ijc.28989</mixed-citation><mixed-citation xml:lang="en">Tsilidis KK, Allen NE, Appleby PN, et al Diabetes mellitus and risk of prostate cancer in the European prospective investigation into cancer and nutrition Int J Cancer. 2015;136(2):372-381. doi: https://doi.org/10.1002/ijc.28989</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lai GY, Park Y, Hartge P, et al. The association between selfreported diabetes and cancer incidence in the NIH-AARP diet and health study. J Clin Endocrinol Metab. 2013;98(3):E497-E502. doi: https://doi.org/10.1210/jc.2012-3335</mixed-citation><mixed-citation xml:lang="en">Lai GY, Park Y, Hartge P, et al. The association between selfreported diabetes and cancer incidence in the NIH-AARP diet and health study. J Clin Endocrinol Metab. 2013;98(3):E497-E502. doi: https://doi.org/10.1210/jc.2012-3335</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lawrence YR, Morag O, Benderly M, et al. Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer Prostatic Dis. 2013;16(2):181-186. doi: https://doi.org/10.1038/pcan.2012.54</mixed-citation><mixed-citation xml:lang="en">Lawrence YR, Morag O, Benderly M, et al. Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer Prostatic Dis. 2013;16(2):181-186. doi: https://doi.org/10.1038/pcan.2012.54</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Fall K, Garmo H, Gudbjornsdottir S, et al. Diabetes mellitus and prostate cancer risk; a nation wide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1102-1109 doi: https://doi.org/10.1158/1055-9965.EPI-12-1046</mixed-citation><mixed-citation xml:lang="en">Fall K, Garmo H, Gudbjornsdottir S, et al. Diabetes mellitus and prostate cancer risk; a nation wide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1102-1109 doi: https://doi.org/10.1158/1055-9965.EPI-12-1046</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Magliano DJ, Davis WA, Shaw JE, et al. Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle diabetes study. Eur J Endocrinol. 2012;167(4):589-599. doi: https://doi.org/10.1530/EJE-12-0053</mixed-citation><mixed-citation xml:lang="en">Magliano DJ, Davis WA, Shaw JE, et al. Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle diabetes study. Eur J Endocrinol. 2012;167(4):589-599. doi: https://doi.org/10.1530/EJE-12-0053</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Attner B, Landin-OlssonM, LithmanT, et al. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes Control. 2012;23(5):769-777 doi: https://doi.org/10.1007/s10552-012-9946-5</mixed-citation><mixed-citation xml:lang="en">Attner B, Landin-OlssonM, LithmanT, et al. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes Control. 2012;23(5):769-777 doi: https://doi.org/10.1007/s10552-012-9946-5</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Moses K A, Utuama O A, Goodman M, et al. The association of diabetes and positive prostate biopsy in a US veteran population Prostate Cancer. Prostatic Dis. 2012;15(1):70-74 doi: https://doi.org/10.1038/pcan.2011.40</mixed-citation><mixed-citation xml:lang="en">Moses K A, Utuama O A, Goodman M, et al. The association of diabetes and positive prostate biopsy in a US veteran population Prostate Cancer. Prostatic Dis. 2012;15(1):70-74 doi: https://doi.org/10.1038/pcan.2011.40</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Samueal VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 2016;1(26):12-22. doi: https://doi.org/10.1172/JCI77812</mixed-citation><mixed-citation xml:lang="en">Samueal VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 2016;1(26):12-22. doi: https://doi.org/10.1172/JCI77812</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Arcidiacono B, Iiritano S, Nocera A, et al. Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms. Exp Diabetes Res. 2012;2012:1-12. doi: https://doi.org/10.1155/2012/789174</mixed-citation><mixed-citation xml:lang="en">Arcidiacono B, Iiritano S, Nocera A, et al. Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms. Exp Diabetes Res. 2012;2012:1-12. doi: https://doi.org/10.1155/2012/789174</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Perks CM, Zielinska HA, Wang J, et al. Insulin receptor isoform variations in prostate cancer cells. Front Endocrinol. 2016;7:132. doi: https://doi.org/10.3389/fendo.2016.00132</mixed-citation><mixed-citation xml:lang="en">Perks CM, Zielinska HA, Wang J, et al. Insulin receptor isoform variations in prostate cancer cells. Front Endocrinol. 2016;7:132. doi: https://doi.org/10.3389/fendo.2016.00132</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Albanes D, Weinstein SJ, Wright ME, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst. 2009;101:1272-1279. doi: https://doi.org/10.1093/jnci/djp260</mixed-citation><mixed-citation xml:lang="en">Albanes D, Weinstein SJ, Wright ME, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst. 2009;101:1272-1279. doi: https://doi.org/10.1093/jnci/djp260</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Darbinian JA, Ferrara AM, Van Den Eeden SK, et al. Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:628-635. doi: https://doi.org/10.1158/1055-9965.EPI-07-2610</mixed-citation><mixed-citation xml:lang="en">Darbinian JA, Ferrara AM, Van Den Eeden SK, et al. Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:628-635. doi: https://doi.org/10.1158/1055-9965.EPI-07-2610</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Preston MA, Riis AH, Ehrenstein V, et al. Metformin use and prostate cancer risk. Eur Urol. 2014;66:1012-1020. doi: https://doi.org/10.1016/j.eururo.2014.04.027</mixed-citation><mixed-citation xml:lang="en">Preston MA, Riis AH, Ehrenstein V, et al. Metformin use and prostate cancer risk. Eur Urol. 2014;66:1012-1020. doi: https://doi.org/10.1016/j.eururo.2014.04.027</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Y, Chen Q, Wang Z, Zhou J. Insulin Therapy and Risk of Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies. PLoS One. 2013;8(11):e81594. doi: https://doi.org/10.1371/journal.pone.0081594</mixed-citation><mixed-citation xml:lang="en">Chen Y, Chen Q, Wang Z, Zhou J. Insulin Therapy and Risk of Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies. PLoS One. 2013;8(11):e81594. doi: https://doi.org/10.1371/journal.pone.0081594</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Cattabiani C, Basaria S, Ceda GP. Luci, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35:104-120. doi: https://doi.org/10.3275/8061</mixed-citation><mixed-citation xml:lang="en">Cattabiani C, Basaria S, Ceda GP. Luci, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35:104-120. doi: https://doi.org/10.3275/8061</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Di Sebastiano KM, Pinthus JH, Duivenvoorden WCM, et al. Elevated c-peptides, abdominal obesity and abnormal adipokine profile are associated with higher Gleason scores in prostate cancer. Prostate. 2017;77:211-221. doi: https://doi.org/10.1002/pros.23262</mixed-citation><mixed-citation xml:lang="en">Di Sebastiano KM, Pinthus JH, Duivenvoorden WCM, et al. Elevated c-peptides, abdominal obesity and abnormal adipokine profile are associated with higher Gleason scores in prostate cancer. Prostate. 2017;77:211-221. doi: https://doi.org/10.1002/pros.23262</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Zamboni PF, Simone M, Passaro A, et al. Metabolic profile in patients with benign prostate hyperplasia or prostate cancer and normal glucose tolerance. Horm Metab Res. 2003;35:296-300. doi: https://doi.org/10.1055/s-2003-41305</mixed-citation><mixed-citation xml:lang="en">Zamboni PF, Simone M, Passaro A, et al. Metabolic profile in patients with benign prostate hyperplasia or prostate cancer and normal glucose tolerance. Horm Metab Res. 2003;35:296-300. doi: https://doi.org/10.1055/s-2003-41305</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Di Sebastiano KM, Bell KE, Mitchell AS, et al. Glucose metabolism during the acute prostate cancer treatment trajectory: The influence of age and obesity. Clin Nutr. 2018;37(1):195-203. doi: https://doi.org/10.1016/j.clnu.2016.11.024</mixed-citation><mixed-citation xml:lang="en">Di Sebastiano KM, Bell KE, Mitchell AS, et al. Glucose metabolism during the acute prostate cancer treatment trajectory: The influence of age and obesity. Clin Nutr. 2018;37(1):195-203. doi: https://doi.org/10.1016/j.clnu.2016.11.024</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Tekdoğan UY, Bağcioğlu M, Özcan S, et al. The effect of oral glucose tolerance test on insulin and some related indicators in elderly male patients with prostate cancer and benign prostate hyperplasia. Turkish J Geriatrics. 2015;18:10-14.</mixed-citation><mixed-citation xml:lang="en">Tekdoğan UY, Bağcioğlu M, Özcan S, et al. The effect of oral glucose tolerance test on insulin and some related indicators in elderly male patients with prostate cancer and benign prostate hyperplasia. Turkish J Geriatrics. 2015;18:10-14.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41(18):2887-2895. doi: https://doi.org/10.1016/j.ejca.2005.09.003</mixed-citation><mixed-citation xml:lang="en">Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41(18):2887-2895. doi: https://doi.org/10.1016/j.ejca.2005.09.003</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Rodriguez C, Patel AV, Mondul AM, et al. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005;161(2):147-152. doi: https://doi.org/10.1093/aje/kwh334</mixed-citation><mixed-citation xml:lang="en">Rodriguez C, Patel AV, Mondul AM, et al. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005;161(2):147-152. doi: https://doi.org/10.1093/aje/kwh334</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Noda T, Kikugawa T, Tanji N, et al. Long-term exposure to leptin enhances the growth of prostate cancer cells. Int J Oncol. 2015;46(4):1535-1542. doi: https://doi.org/10.3892/ijo.2015.2845</mixed-citation><mixed-citation xml:lang="en">Noda T, Kikugawa T, Tanji N, et al. Long-term exposure to leptin enhances the growth of prostate cancer cells. Int J Oncol. 2015;46(4):1535-1542. doi: https://doi.org/10.3892/ijo.2015.2845</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Keating NL, O’Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39-46. doi: https://doi.org/10.1093/jnci/djp404</mixed-citation><mixed-citation xml:lang="en">Keating NL, O’Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39-46. doi: https://doi.org/10.1093/jnci/djp404</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Crawley D, Garma H, Rudman S, et al. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Int J Cancer. 2016;139:2698-2704. doi: https://doi.org/10.1002/ijc.30403</mixed-citation><mixed-citation xml:lang="en">Crawley D, Garma H, Rudman S, et al. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Int J Cancer. 2016;139:2698-2704. doi: https://doi.org/10.1002/ijc.30403</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Dennis RJ, Maldonado D, Rojas MX, et al. Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study. BMC Pulm Med. 2010;10:38. doi: https://doi.org/10.1186/1471-2466-10-38</mixed-citation><mixed-citation xml:lang="en">Dennis RJ, Maldonado D, Rojas MX, et al. Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study. BMC Pulm Med. 2010;10:38. doi: https://doi.org/10.1186/1471-2466-10-38</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73:602-612. doi: https://doi.org/10.1111/j.1365-2265.2010.03845.x</mixed-citation><mixed-citation xml:lang="en">Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73:602-612. doi: https://doi.org/10.1111/j.1365-2265.2010.03845.x</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Thong MSY, van de Poll-Franse L, Hoffman RM et al. Diabetes mellitus and health-related quality of life in prostate cancer: 5- year results from the Prostate Cancer Outcomes Study. BJU Int. 2010;107:1223-1231. doi: https://doi.org/10.1111/j.1464-410X.2010.09861.x</mixed-citation><mixed-citation xml:lang="en">Thong MSY, van de Poll-Franse L, Hoffman RM et al. Diabetes mellitus and health-related quality of life in prostate cancer: 5- year results from the Prostate Cancer Outcomes Study. BJU Int. 2010;107:1223-1231. doi: https://doi.org/10.1111/j.1464-410X.2010.09861.x</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-578. doi: https://doi.org/10.1093/annonc/mdr603</mixed-citation><mixed-citation xml:lang="en">Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-578. doi: https://doi.org/10.1093/annonc/mdr603</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res. 2011;4:486-501. doi: https://doi.org/10.1158/1940-6207.CAPR-10-0229</mixed-citation><mixed-citation xml:lang="en">Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res. 2011;4:486-501. doi: https://doi.org/10.1158/1940-6207.CAPR-10-0229</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63:800-809. doi: https://doi.org/10.1016/j.eururo.2012.11.013</mixed-citation><mixed-citation xml:lang="en">Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63:800-809. doi: https://doi.org/10.1016/j.eururo.2012.11.013</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer — a dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23:1665-1671. doi: https://doi.org/10.1093/annonc/mdr603</mixed-citation><mixed-citation xml:lang="en">Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer — a dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23:1665-1671. doi: https://doi.org/10.1093/annonc/mdr603</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Rowlands MA, Gunnell D, Harris R, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer. 2009;124:2416-2429. doi: https://doi.org/10.1002/ijc.24202</mixed-citation><mixed-citation xml:lang="en">Rowlands MA, Gunnell D, Harris R, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer. 2009;124:2416-2429. doi: https://doi.org/10.1002/ijc.24202</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Kapoor D, Malkin CJ, Channert KS, et al. Androgens insulin resistance and vascular disease in men. Clin Endocrinol (Oxf ). 2005;63:239-250. doi: https://doi.org/10.1111/j.1365-2265.2005.02299.x</mixed-citation><mixed-citation xml:lang="en">Kapoor D, Malkin CJ, Channert KS, et al. Androgens insulin resistance and vascular disease in men. Clin Endocrinol (Oxf ). 2005;63:239-250. doi: https://doi.org/10.1111/j.1365-2265.2005.02299.x</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Alshaker H, Sacco K, Alfraidi A, et al. Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma. Oncotarget. 2015;6:35556-35563. doi: https://doi.org/10.18632/oncotarget.5574</mixed-citation><mixed-citation xml:lang="en">Alshaker H, Sacco K, Alfraidi A, et al. Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma. Oncotarget. 2015;6:35556-35563. doi: https://doi.org/10.18632/oncotarget.5574</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Nigro E, Scudiero O, Monaco ML, et al. New Insight into Adiponectin Role in Obesity and Obesity-Related Diseases. Biomed Res Int. 2014;2014:1-14. doi: https://doi.org/10.1155/2014/658913</mixed-citation><mixed-citation xml:lang="en">Nigro E, Scudiero O, Monaco ML, et al. New Insight into Adiponectin Role in Obesity and Obesity-Related Diseases. Biomed Res Int. 2014;2014:1-14. doi: https://doi.org/10.1155/2014/658913</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Goktas S, Yilmaz MI, Caglar K, et al. Prostate cancer and adiponectin. Urologia. 2005;65:1168-1172. doi: https://doi.org/10.3233/CBM-160467</mixed-citation><mixed-citation xml:lang="en">Goktas S, Yilmaz MI, Caglar K, et al. Prostate cancer and adiponectin. Urologia. 2005;65:1168-1172. doi: https://doi.org/10.3233/CBM-160467</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006;94:1221-1225. doi: https://doi.org/10.1038/sj.bjc.6603051</mixed-citation><mixed-citation xml:lang="en">Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006;94:1221-1225. doi: https://doi.org/10.1038/sj.bjc.6603051</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Paris M, Mourtzakis M. Assessment of skeletal muscle mass in critically ill patients: considerations fot the utility of computed tomography images and ultrasonography. Curr Opin Clin Nutr Metab Care. 2016;19:125-130. doi: https://doi.org/10.1097/MCO.0000000000000259</mixed-citation><mixed-citation xml:lang="en">Paris M, Mourtzakis M. Assessment of skeletal muscle mass in critically ill patients: considerations fot the utility of computed tomography images and ultrasonography. Curr Opin Clin Nutr Metab Care. 2016;19:125-130. doi: https://doi.org/10.1097/MCO.0000000000000259</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Z, Maricic M, Nguyen P, et al. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 2002;95:2136-2144. doi: https://doi.org/10.1002/cncr.10967</mixed-citation><mixed-citation xml:lang="en">Chen Z, Maricic M, Nguyen P, et al. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 2002;95:2136-2144. doi: https://doi.org/10.1002/cncr.10967</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Muller M, Grobbee DE, Tonkelaar I, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90:2618-2623. doi: https://doi.org/10.1210/jc.2004-1158.</mixed-citation><mixed-citation xml:lang="en">Muller M, Grobbee DE, Tonkelaar I, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90:2618-2623. doi: https://doi.org/10.1210/jc.2004-1158.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
